Posted on February 24, 2008 by shsiong
by Susan Hsiong, PhD
More than 12 million minimally invasive vascular surgeries are done every year. These [...]
Filed under: AccessClosure, Biomaterials, Datascope, NeoMend, PEG-based Biomaterials, St. Jude Medical, Vascular Closure, biomaterial devices, vascular regeneration | Tagged: AccessClosure, biomaterial devices, catheterization, endovascular, Mynx, NeoMend, ProGEL, vascular closure devices | No Comments »
Posted on January 29, 2008 by jrowley
You have to hand it to Tengion, they are trying to tackle one of the largest challenges I can think of: producing tissue engineered organs and tissues from a patients own cells in unrelated indications (bladder, blood vessel, and kidney). While moving through clinical trials Tengion will surely be transforming patients lives with these [...]
Filed under: Biomaterials, Bioprocessing, Clinical Trials, Company Profiles, JNJ, Regenerative Medicine, Tengion, autologous, combination products, patient specific cell therapy, personalized medicine, tissue engineered product, vascular regeneration | Tagged: autologous therapies, company prifile, tissue engineering company | 3 Comments »
Posted on January 22, 2008 by jrowley
Pervasis Therapeutics announced that they have raised $9.75M to further develop their allogenic tissue engineered endothelial cell (EC) product for vascular health indications. Their Vascugel product is comprised of ECs grown in 3D collagen sponges that are implanted externally on blood vessels to prevent them from occluding. Pervasis has proven safety in a Phase I [...]
Filed under: Biomaterials, Bioprocessing, Clinical Trials, Company Profiles, Manufacturing, Pervasis, Regenerative Medicine, cell delivery, combination products, tissue engineered product, vascular regeneration | Tagged: end stage renal disease, endothelial cells, ESRD, gelfoam, tissue engineering, vascular health | No Comments »
Posted on January 18, 2008 by shsiong
When we have a cold or a headache, we pop a pill. We get sick, we go to the doctor and get a shot. Taking medication orally via a pill or getting drugs injected via a syringe are some of the oldest forms of delivering therapeutic molecules. In the past, [...]
Filed under: Biomaterials, Mimetic Solutions, Regenerative Medicine, Smart materials, biomimetics therapeutics, combination products, controlled release, diabetes | Tagged: controlled release, diabetes, drug delivery, mimetics, Mimetics Solutions | No Comments »
Posted on January 8, 2008 by shsiong
by Susan Hsiong, PhD
Biomimetics Therapeutics, Inc. (Franklin, TN), a company which develops drug-device combination products for orthopedic applications, recently announced positive results from its Canadian clinical study evaluating its GEM OS®1 Bone Graft for the open surgical treatment of foot and ankle fusions. The GEM OS®1 is a combination product comprised of a [...]
Filed under: Biomaterials, Company Profiles, Medtronic, Regenerative Medicine, biomimetics therapeutics, bone regeneration, combination products, controlled release | Tagged: biomimetics therapeutics, bone graft substitutes, bone healing, combination products, controlled release, GEM OS1, Infuse, orthopedics, recombinant protein products | 3 Comments »
Posted on January 4, 2008 by jrowley
I have recently signed up for the StemCellPatents.com weekly newsletter, and it is great to keep updated on all the patents that get issued in regenerative medicine. In the most recent newletter, they reported on two patents that issued last week that strengthen Celgene’s patent estate in adult stem cells. Celgene got into the stem [...]
Filed under: Biomaterials, Celgene, Intellectual Property, Regenerative Medicine, adult stem cell, placenta stem cells, stem cells | Tagged: acquisition, Anthrogenesis, Celgene, patent strategy, placenta stem cells | 1 Comment »
Posted on December 23, 2007 by jrowley
Athersys and their cardiac parter, Angiotech, announced today that they got the ok from the FDA to begin a Phase I clinical study using Athersys’ Multistem adult stem cell product in acute myocardial infarction (MI). This is the second IND approval for Athersys in just over a month (and a welcome Christmas present for [...]
Filed under: Angiotech, Athersys, Biomaterials, Clinical Trials, Joint Ventures, Regenerative Medicine, cardiac regeneration, cell delivery | Tagged: Angiotech, Athersys, cardiac cell therapy, cell delivery, IND | No Comments »
Posted on December 9, 2007 by jrowley
The regenerative medicine industry is banking on cellular therapy to help regenerate tissues and restore function in clinical indications with high unmet needs. The mechanism of action, or how stem cells actually drive tissue regeneration, is still hotly debated - but it is likely a mixture of several actions (see item #6 in this post) [...]
Filed under: Biomaterials, Regenerative Medicine, business models | Tagged: biomaterials as therapeutics, business models, Regenerative Medicine | 1 Comment »
Posted on December 1, 2007 by jrowley
Osiris Therapeutics last week announced positive data that came out of their Phase I/II double blinded Chondrogen trial. They demonstrated statistically significant improvements in joint pain in patients with osteoarthritis, however this seems to be an about face compared to when they announced their “disappointing” (the CEO’s words) interim 6 [...]
Filed under: Biomaterials, Clinical Trials, Osiris, Regenerative Medicine, adult stem cell, cartilage, orthopedics, stem cells | 1 Comment »
